Autoimmune giant cell myocarditis – clinical characteristics, experimental models and future treatments
Authors:
- 8 July 2011
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 15 (10) , 1163-1172
Abstract
(2011). Autoimmune giant cell myocarditis – clinical characteristics, experimental models and future treatments. Expert Opinion on Therapeutic Targets: Vol. 15, No. 10, pp. 1163-1172.Keywords
This publication has 50 references indexed in Scilit:
- The Anti-Inflammatory Mechanism of Prostaglandin E2 Receptor 4 Activation in Rat Experimental Autoimmune MyocarditisJournal of Cardiovascular Pharmacology, 2011
- Effects of specific chemical suppressors of plasminogen activator inhibitor-1 in cardiovascular diseasesExpert Opinion on Investigational Drugs, 2011
- Cutting Edge: CTLA-4–B7 Interaction Suppresses Th17 Cell DifferentiationThe Journal of Immunology, 2010
- Usefulness of Immunosuppression for Giant Cell MyocarditisThe American Journal of Cardiology, 2008
- Interleukin-13 Protects Against Experimental Autoimmune Myocarditis by Regulating Macrophage DifferentiationThe American Journal of Pathology, 2008
- T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17Journal of Experimental Medicine, 2006
- A CCR1 antagonist prevents the development of experimental autoimmune myocarditis in association with T cell inactivationJournal of Molecular and Cellular Cardiology, 2006
- A cyclooxygenase-2 inhibitor alters Th1/Th2 cytokine balance and suppresses autoimmune myocarditis in ratsJournal of Molecular and Cellular Cardiology, 2006
- Hepatocyte Growth Factor Ameliorates the Progression of Experimental Autoimmune MyocarditisCirculation Research, 2005
- A Case of giant cell myocarditis and malignant thymoma: A postmortem diagnosis by needle biopsyClinical Cardiology, 1998